Patients who use drugs containing semaglutide are at an increased risk of gastroparesis, according to an October 2023 medical journal article about patients who used two different types of weight-loss drugs. The Novo Nordisk drugs Wegovy, Rybelsus, and Ozempic each have semaglutide as their active ingredient. Accordingly, Wegovy, Rybelsus, and Ozempic were linked to gastroparesis by the findings presented in this article. As regards possible gastroparesis drug injury lawsuits against Novo Nordisk, the better cases will involve non-diabetic patients who used Wegovy as intended for weight loss and people without diabetes who used Rybelsus or Ozempic “off-label” to lose weight. This is because the medical condition diabetes, itself, is a known cause of gastroparesis.
The medical journal article we referred to above is titled “Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss”. This article was published on October 5, 2023, by the Journal of the American Medical Association (JAMA), and it presented the results of a recent medical study in which semaglutide drugs such as Wegovy, Rybelsus, and Ozempic were compared to Contrave, a drug which does not contain semaglutide. That medical study found the use of drugs containing semaglutide was associated with an increased risk of gastroparesis.
We are investigating possible gastroparesis drug injury lawsuits against Novo Nordisk for people who have not been diagnosed with diabetes and were using Rybelsus or Ozempic “off-label” as a weight-loss treatment. In addition, we are investigating gastroparesis cases involving Wegovy used by people who do not have diabetes.
Feel free to contact us about possible gastroparesis drug injury lawsuits involving Wegovy, Rybelsus, or Ozempic. We want to be clear that these cases would be filed against Novo Nordisk, the responsible drug company (and not your doctor).[Read article in full at original source]
Strictly Confidential, No Obligation